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ABSTRACT 
Objectives: The Psoriatic Arthritis Impact of Disease questionnaire (PsAID) is a recently developed 
patient reported outcome measure (PROM) of disease impact in psoriatic arthritis (PsA). We set out 
to assess the validity in an independent cohort of patients, estimate the minimally important 
difference for improvement and explore the potential of individual components of the PsAID in 
clinical practice.     
Methods: Data were collected prospectively for a single-centre cohort of PsA patients.  Construct 
validity was assessed by Spearman correlation with other PROMs and reliability by intraclass 
correlation coefficient (ICC) at 1 week.  Sensitivity to change at 3 months was determined by the 
standardised response mean (SRM) in those patients with active disease requiring a change in 
treatment.    
Results: A total of 129 patients (mean±SD age 52.1±13.3, 57% female, disease duration 10.2±8 
years) completed the baseline questionnaires and assessments.  The mean baseline PsAID12 score 
was 3.92±2.26 with an ICC of 0.91 (95%CI 0.87-0.94).  The standard error of measurement was 0.51 
and the minimal detectable change was 1.41. There was strong correlation (r≥0.70) with most of the 
PROMs studied and moderate correlation with clinical outcomes (r=0.40-0.57). The SRM of the 
PsAID12 was 0.74 (95%CI 0.45-0.97). There was strong correlation with individual PsAID items and 
their corresponding PROM questionnaires (r≥0.67).  
Conclusion: The PsAID is a reliable, feasible and discriminative measure in patients with psoriatic 
arthritis. The good responsiveness of the PsAID and strong correlation of individual items with other 
PROMS represents an opportunity to reduce questionnaire burden for patients in studies and clinical 
practice. 
Keywords: Psoriatic Arthritis, Outcomes research, Disease activity, Patient perspective, DMARDs 
(biologic)  
INTRODUCTION 
Psoriatic Arthritis (PsA) is a chronic inflammatory arthropathy affecting up to 30% of patients with skin 
or nail psoriasis,[1].  Psoriasis is a complex disease, and has a multitude of clinical manifestations 
including skin and nail disease, dactylitis, enthesitis, peripheral arthritis, and axial disease.  This 
complexity has resulted in the development of a number of disease activity indices to best capture the 
clinical manifestations of disease, all of which perform similarly and use a ‘biomedical model’ for 
determining disease activity,[2].  Disease activity and damage contribute to reduced physical and 
psychosocial health-related quality of life, with significant social and economic impact,[3].  
 
Patient reported outcome measures (PROMs) have been found to be a reliable indicator of baseline 
status, change during treatment and are predictive of long-term outcome,[4-6]. The updated core 
domain set for PsA includes Patient Global Assessment (PGA), physical function (such as the Health 
Assessment Questionnaire, HAQ), fatigue and health related quality of life in the inner core,[7].  A 
recent literature review indicated that pain, PGA and HAQ were frequently measured in clinical trials, 
however other measures of how the patient feels or functions, such as fatigue and sleep, were rarely 
reported,[8].  The Short-Form 36 (SF-36), whilst a recognised measure of the economic impact of 
disease, is long and the interpretation of the score is complex.  The HAQ has also been shown to 
change with disease duration and less reliably reflects disease activity in well-established disease,[9].  
 
A EULAR taskforce developed a questionnaire to calculate a score reflecting the impact of psoriatic 
arthritis from the patients’ perspective, termed the Psoriatic Arthritis Impact of Disease (PsAID) 
questionnaire,[10].  Development of this questionnaire was driven by the patient perspective and 
involved 12 patient research partners from 12 countries all with personal experience of PsA.  The 
taskforce determined 12 domains important to health and well-being, including fatigue, functional 
capacity, sleep and coping.  The PsAID questionnaire was validated with more than 470 patients, and 
had good face validity and good generalizability and also correlated strongly with patient global 
assessment.  The questionnaire has been divided into two scores; the PSAID12 uses all 12 items and 
was designed to be used in clinical practice, and the PsAID9 uses the first 9 items and was designed to 
be used in clinical trials. The authors commented that further validation in independent cohorts would 
be necessary, in particular sensitivity to change. 
 
The Outcome Measures in Rheumatology (OMERACT) filter,[11] assess the applicability of a measure 
and looks at three aspects: Truth, Discrimination and Feasibility.  A measure is useful if it measures 
what is intended, is reliable and sensitive, and can be applied easily.  The PsAID has been designed to 
conform to these principals, but requires further validation, in particular regarding sensitivity to 
change in comparison with other outcome measures, both clinical and patient reported. The PsAID 
includes items related to work, fatigue and physical function, all components of the inner core in the 
PsA Core Domain Set.  A single questionnaire could therefore be used in routine clinical care to assess 
these domains, reducing patient burden.  The aim of the study was to further investigate the PsAID in 
a new cohort to determine reliability, construct validity, sensitivity to change, to validate the minimal 
clinically important improvement and investigate the correlation of individual questions of the PsAID 
with established PROMS. 
 
METHODS 
Study Design 
Data were collected prospectively from patients attending the Royal National Hospital for Rheumatic 
Diseases, Bath UK, from July 2015 until January 2017.  The cohort was divided into two groups based 
on disease activity, with the data from group two used to determine sensitivity to change.  Patients 
with stable disease not requiring a change in treatment (patient and physician opinion) were recruited 
to group one.  Patients with active disease requiring a change in treatment were recruited to group 
two.  Clinical measures and PROs including the PsAID were completed at baseline by both groups and 
the PsAID questionnaire was repeated at one week and returned by post.  Patients in group two 
attended for follow-up 3 months after a change in treatment.  For each patient, written informed 
consent was obtained, and the study was approved by the relevant ethics committee. 
 
Inclusion criteria 
To be eligible for the study, patients had to fulfil ClASsification of Psoriatic Arthritis (CASPAR) 
diagnostic criteria for PsA[12].  For patients in group two, an intensification of therapy was defined as: 
(i) an increase in the dose of the current conventional synthetic disease modifying anti-rheumatic 
drug(s) (csDMARDs); (ii) initiation of new csDMARD(s); (iii) initiation of a new, or change of the current, 
biological DMARD (bDMARD).  Patients were excluded from the study if they were under the age of 
18, were unable to speak and read English, had an additional inflammatory disease other than 
Psoriatic disease, or severe, unstable co-morbidities that could influence the PROMs.   
 
Data collection 
Demographic data were collected at baseline including age, gender, disease duration, smoking status, 
body mass index (BMI), and the presence or absence of erosive disease on x-ray.  At baseline (both 
groups) and at 3 months (group two) patients completed the Health Assessment Questionnaire – 
Disability Index (HAQ-DI,[13]), EuroQol questionnaire (EQ5D-5L,[14,15]), Psoriatic Arthritis Quality of 
Life questionnaire (PsAQoL,[16]), Dermatology Life Quality Index (DLQI,[17]), Work Productivity and 
Activity Impairment: Specific Health Problem Questionnaire (WPAI:SHP,[18]) and visual analogue scale 
(VAS) scores for patient global assessment (PGA), and joint global assessment (JtGA).  All patients 
underwent a full clinical assessment at baseline, and a 66/68 swollen (SJC) and tender (TJC) joint count, 
dactylitis score, Leeds enthesitis index (LEI,[19]), Bath nail score,[20], Psoriasis Activity and Severity 
Index (PASI,[21]), physician global VAS (PhGA) and C-reactive protein (where possible) were recorded.  
The modified Composite Disease Activity Index (mCPDAI,[22]) was used as a composite measure of 
disease activity.   
 
Patients in group two had a further clinical assessment at follow-up, and in addition were asked “which 
statement best describes your arthritis today compared to 3 months ago?” a) Overall my condition is 
improved; b) Overall, my condition is stable; c) Overall, my condition is worse.  If patients indicated 
their condition had improved, they were also asked to rate the improvement as somewhat significant, 
moderately significant, or very significant.  The PsAID questionnaire was completed at baseline, 1-
week and 3-months (follow-up, group two only). 
 
Statistical Analysis 
Internal consistency of the PsAID scoring tool was evaluated using Cronbach’s α coefficient, with a 
value greater than 0.7 indicating consistency.  Relative reliability of the PsAID was tested with the 
intraclass correlation coefficient (ICC, two-way mixed model absolute agreement), and variability was 
assessed using the Bland-Altman method,[23].  Absolute reliability was determined by the standard 
error of measurement (SEM), indicating the variability in scores upon repeated testing.  The SEM was 
determined using 𝑆𝐸𝑀 = 𝑆𝐷 ×√(1 − 𝑟𝑒𝑙𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦),[24].  The minimal detectable change (MDC), 
representing the magnitude of change required to exceed the measurement error, was calculated for 
the 95% confidence interval as 𝑀𝐷𝐶 = 𝑆𝐸𝑀 × 1.9 × √2,[25]. 
 
Construct validity was assessed using Spearman rank correlation coefficient as the PROM scores were 
not normally distributed (Shapiro-Wilk test).  Sensitivity to change was calculated using the 
standardised response mean (SRM, the mean change between baseline and 3 months divided by the 
SD of the change) with the analysis done on a per protocol basis.  An SRM greater than 0.8 is 
considered large. Confidence intervals were calculated by boot-strap.  
 
The Minimal Clinically Important Improvement (MCII) was estimated using receiver operating 
characteristic curves, plotted using improvement versus no improvement as the outcome, and the 
minimal clinically relevant improvement was computed as the change score that had maximal 
sensitivity whilst maintaining a specificity of 0.80.  This measure indicates the degree of change that 
80% or more of patients would indicate as important.   
 
The correlation between individual items of the PsAID questionnaire and specific patient-reported 
outcome questionnaires was evaluated.  The domains studied were fatigue (FACIT-fatigue, compared 
with item 2 of the PsAID questionnaire), skin disease (DLQI, compared with item 3), work (WPAI:SHP, 
compared with item 4 and item 11), function (HAQ, compared with item 5) and quality of life (PsAQoL, 
compared with the PsAID12).  To enable direct comparison with the PsAID items, the studied PROM 
questionnaires were transformed to a 0-10 scale.  In the case of the FACIT-Fatigue, where higher 
scores indicate less fatigue, the scale was reversed so that a score of 0 indicated no fatigue and 10 
indicated maximum fatigue.  Correlation was determined using Spearman rank correlation coefficient.  
Bland-Altman plots with 95% upper and lower limits of agreement were constructed to examine the 
differences, using both absolute differences (score A – score B) and relative differences (score A – 
score B/mean%)[26].  Statistical analysis was performed using SPSS version 22.0. 
 
RESULTS 
A total of 159 patients were screened and recruited to the study; 129 patients satisfactorily completed 
the required baseline questionnaires and assessments.  Demographic data for the cohort is presented 
in Table 1. The mean±SD baseline PsAID12 score was 3.92±2.36 and the mean baseline PsAID9 score 
was 4.11±2.40.  The mean re-test PsAID 12 score was 3.55±2.26 and the mean re-test PsAID9 score 
was 3.72±2.30.  Cronbach’s alpha was 0.95 and Tthe intraclass correlation coefficient (ICC) was 0.91 
(95% CI 0.87-0.94) and 0.91 (0.86-0.94) for the PsAID12 and PsAID9 respectively indicating excellent 
reliability.  Corresponding values for group 1 only were Cronbach’s alpha 0.96, ICC 0.92 (0.87-0.96) 
and 0.92 (0.86-0.95) for PsAID12 and 9 respectively.  There were very few missing items (<0.5%) 
indicating excellent feasibility.  The variability in test-retest scores is shown in Figure 1.  There was no 
proportional bias.  The SEM was 0.51 and the minimal detectable change was 1.41. 
 
Table 1. Baseline demographics for the total cohort and the sensitivity to change arm 
 
 Total Cohort (n=129) Sensitivity to Change 
(n=53) 
Age, Mean ± sd 52.1 ± 13.3 48.0 ± 14.0 
Disease duration, Mean 
± sd 
10.2 ±7.8 9.5 ± 8.8 
BMI, Mean ± sd 29.2 ± 5.9 28.9 ± 5.5 
Sex, M (%) 55 (42.6) 22 (41.5%) 
Erosive disease, Yes (%) 50 (38.8) 19 (35.8%) 
Smoker, Yes (%) 19 (14.7) 8 (15.1%) 
SJC, Median (range) 1 (0-15) 2 (0-15) 
TJC, Median (range) 6 (0-54) 8 (0-50) 
PASI, Median (range) 0.2 (0-7.9) 0.3 (0-7.9) 
LEI, Median (range) 0 (0-6) 0 (0-4) 
Dactylitis, Median 
(range) 
0 (0-7) 0 (0-4) 
mCPDAI, Median 
(range) 
3 (0-10) 3 (0-10) 
 
 
There was strong correlation between the PsAID and most PROMs as shown in Table 2, with 
Spearman’s rank correlation coefficient greater than 0.60.  The strongest correlation was with the 
EQ5D Index score (-0.87), followed by the BASDAI and FACIT-Fatigue.  There was moderate correlation 
between the PsAID and joint counts (Spearman’s rho of 0.57 and 0.40 for tender and swollen joint 
counts respectively) and mCPDAI score (0.57).  There was no correlation between the PsAID score and 
the PASI, possibly due to the minimal skin disease in the patient population (mean PASI 0.6 indicating 
very mild skin disease). 
 
Table 2. Association between PsAID and clinical and patient reported outcomes (Spearman 
correlation coefficient)  
 
 
PsAID12 
PsAID12 
(Males) 
PsAID12 
(Females) 
EQ5D Index -0.87 -0.90 -0.80 
BASDAI 0.84 0.93 0.74 
FACIT-Fatigue -0.84 -0.80 -0.86 
PsAQoL 0.80 0.84 0.77 
Work Impairment 0.75 0.75 0.67 
PGA 0.70 0.76 0.60 
HAQ 0.70 0.83 0.56 
EQ5D VAS -0.70 -0.83 -0.57 
Presenteeism 0.69 0.61 0.68 
DLQI 0.36 0.39 0.36 
PhGA 0.61 0.74 0.41 
TJC 0.57 0.65 0.42 
mCPDAI 0.57 0.63 0.44 
SJC 0.40 0.46 0.29 
PASI -0.075 0.03 -0.01 
 
 The PsAID score did not change significantly when stratified by disease duration, age, BMI, or the 
presence or absence of erosive disease (data not shown).  Notably, the PsAID score was higher in 
females with a mean score of 4.44±2.13 vs 3.23±2.50 in females and males respectively, with females 
scoring significantly higher in 8 of the 12 items.  This compared similarly to the other recorded PROMs 
in this cohort, with higher scores seen in females for all patient reported outcome measures except 
DLQI.  The correlation with PROMs and clinical outcomes was also stronger in males than in females 
(Table 2). 
 
To determine the minimal clinically important improvement, an ROC curve was constructed using 
improved (overall, my condition has improved) vs not improved (overall, my condition is stable or 
worse) as the outcome (Figure 2, supplementary data).  The AUC was 0.821.  The change in PsAID 
score with greatest sensitivity whilst maintaining a specificity of 80% was 1.25 (sensitivity 61%, 
specificity 80%).  Furthermore, an ROC curve was constructed with improvement defined as a relative 
improvement in PsAID score at 3 months of 30%.  Again, an absolute change score of 1.25 had the 
greatest sensitivity and specificity (74% and 77% respectively).  In this cohort, using the previously 
proposed cut-off of three to define a MCII10 specificity was 100% but sensitivity was only 29%. 
 
Sensitivity to change was assessed in those patients who remained on increased therapy at the time 
of their follow-up assessment.  The SRM of the PsAID12 was 0.74 (95%CI 0.45-0.97).   In comparison, 
the SRM of the mCPDAI was 0.71 (0.35-1.01). 
 
The individual items of the PsAID questionnaire typically scored higher than the PROM questionnaires 
(Table 3).  There was strong correlation between PsAID item and corresponding PROM questionnaire, 
with Spearman correlation coefficients >0.70 (Table 4, supplementary data), with the strongest 
correlation seen in the domains of fatigue and skin disease. Variability was assessed using Bland-
Altman plots (see supplementary data, Figures 3-13).  There was significant variability in the scores, 
with upper limits of agreement ranging from 2.9 to 5.22 and lower limits of agreement -4.0 to -1.97.  
Bland-Altman plots of the percentage difference in scores showed that at mean scores greater than 
five the PsAID item score more closely approximated the PROM questionnaire score. 
 
Table 3. PROM score vs PsAID Item score and differences 
 
 Score (mean ± sd) 
Difference between 
scores 
(mean(95%CI)) 
95% Upper and Lower Limits 
of Agreement of the scores 
FACIT-Fatigue vs 
PsAID Item 2 
4.04 ± 2.5 
0.96 (0.63-1.29) 4.25, -2.33 
5.00 ± 3.1 
DLQI vs 
PsAID Item 3 
0.87 ± 1.2 
1.50 (1.17 – 1.82) 4.96, -1.97 
2.39 ± 2.6 
WPAI-SHP vs 
PsAID Item 4 
2.85 ± 2.8 
0.70 (0.18 – 1.21) 4.56, -3.17 
3.54 ± 2.9 
HAQ vs 
PsAID Item 5 
3.20 ± 2.6 
1.02 (0.62 – 1.41) 5.22, -3.19 
4.30 ± 2.8 
PsAQoL vs 
PsAID12 
4.53 ± 3.0 
-0.53 (-0.85 – -0.22) 2.90, -4.00 
3.97 ± 2.4 
 
 
 
DISCUSSION 
We have demonstrated that the PsAID questionnaire is a reliable measure of the impact of disease in 
a UK cohort of patients with psoriatic arthritis, with the 9-item and 12-item questionnaires performing 
similarly.  The questionnaire was also feasible with a very low number of missing items.  With a mean 
difference of 0.10 (95% CI -0.10 – 0.31) there was only minor variability in baseline and 1-week scores 
despite including patients with both stable and active disease.  Unlike similar instruments used in RA 
(the Rheumatoid Arthritis Impact of Disease, RAID,[13]) there was no obvious floor effect.  
 
The significant difference between mean scores for males and females has not been previously 
demonstrated for the PsAID questionnaire and requires further investigation.  In this cohort, baseline 
demographics were similar between males and females, although males had significantly longer 
disease duration (mean 11.8 vs 9.1 years).  Females had higher tender (11.1 vs 6.4) and swollen (2.6 
vs 1.8) joint counts as well as higher mCPDAI scores (3.4 vs 2.6), but after adjusting for disease activity 
the difference in PSAID score remained significant.  A similar difference was noted with the RAID score, 
as well as other PROMs in psoriatic arthritis including HAQ,[276], and may need to be taken into 
account when interpreting scores.  Di Carlo et al assessed construct validity and reliability in an Italian 
cohort, and noted similar results to this study.  In addition, PsAID scores were higher in patients with 
concomitant fibromyalgia.  Although not reviewed in our cohort, co-existent fibromyalgia may have 
contributed to the gender difference found in our study. 
 
The PsAID questionnaire correlated strongly with other patient reported outcome measures, with the 
strongest correlation with the EQ5D-index score.  This is perhaps not surprising given the EQ5D-Index 
questionnaire includes the domains of mobility, function, usual activities, pain and mental health, 
which are similar to the domains assessed in the PsAID questionnaire.  The correlation with the FACIT-
fatigue is interesting, and ongoing fatigue despite adequate control of psoriatic disease may be may 
be one of the main drivers of disease impact.  The moderate correlation with clinical outcomes is also 
expected, as domains such as work, sleep and fatigue are major determinants of disease impact yet 
are not captured by clinical scores. 
 
The minimal clinically important improvement of 1.25 in the PsAID score in this cohort is significantly 
less than the MCII of 3.0 in the preliminary validation of the PSAID questionnaire.  In this study, the 
majority of patients had a change of DMARD (increased dose or additional agent), and only 29% had 
a change of biological DMARD (change or new biologic agent).  This may have resulted in a lower mean 
change in PsAID score in this study compared to the study by Gossec et al in which 50% of patients 
were commenced on a biological DMARD.  In addition, patients were included if they had a change in 
DMARD dose, which may have also affected the MCII determined in this study. 
 
The PsAID was found to be sensitive to change, with a standardised response mean of 0.74 which was 
greater than the standardised response mean for the mCPDAI score (0.71), although this was lower 
than the SRM as determined in the preliminary validation of the PsAID (Gossec et al).  Although not a 
measure of disease activity, the PsAID questionnaire could be a useful outcome measure to guide 
treatment. 
 
The individual items of the PsAID questionnaire correlated strongly with the corresponding PROM 
questionnaire, particularly between item two (fatigue) and the FACIT-Fatigue and item three (skin) 
and the DLQI.  When examining the differences using Bland-Altman plots, we found that the individual 
PsAID item was typically scored higher than the PROM.  The upper and lower limits of agreement were 
clinically significant, with a mean upper limit of agreement of 4.4 and a mean lower limit of agreement 
of -2.9.  Given the wide 95% levels of agreement seen in this study, the individual PsAID items may not 
be able to accurately estimate a PROM score.  As the PsAID items are disease specific, and 
questionnaires such as the HAQ and FACIT-Fatigue are not, co-morbid conditions in some patients 
may have contributed to some of this variability. However, the strong linear relationship between 
individual items and corresponding PROMs does indicate that the PsAID questionnaire is able to 
highlight domains that are of most concern for a patient, particularly as the percentage difference 
between the scores was significantly less at higher mean scores.  The PsAID questionnaire could 
therefore be used to tailor treatment at an individual level, targeting the domains that are of most 
concern for the patient.  This would eliminate the need for multiple PROM questionnaires at every 
visit, reducing questionnaire burden and fatigue especially in routine outpatient care. 
 
The limitations of this study areis the low number of patients in the sensitivity to change arm who had 
a significant response to a change in treatment, and a formal calculation of sample size was not 
performed.  Additional data from interventional clinical trials, particularly of biologic DMARDs, will be 
useful in confirming the ability of the PsAID to detect change and further validating the MCII. 
 
In summary, the PsAID is a reliable, feasible and valid measure of the impact of disease in patients 
with psoriatic arthritis.  It can be used in patient with both stable and active disease, correlates well 
with clinical and patient reported outcome measures, and can be used to tailor treatment to the 
individual. 
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